Janus Henderson Group PLC Purchases 203,010 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Janus Henderson Group PLC lifted its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 5.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,159,888 shares of the company's stock after purchasing an additional 203,010 shares during the quarter. Janus Henderson Group PLC owned 7.26% of Structure Therapeutics worth $112,816,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd increased its position in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after buying an additional 553 shares in the last quarter. GAMMA Investing LLC lifted its stake in Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after purchasing an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in Structure Therapeutics in the 4th quarter valued at about $40,000. Virtus ETF Advisers LLC lifted its position in shares of Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after acquiring an additional 455 shares in the last quarter. Finally, Assetmark Inc. lifted its holdings in shares of Structure Therapeutics by 72.3% in the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after buying an additional 953 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Stock Performance

Shares of GPCR stock traded up $0.74 during mid-day trading on Friday, reaching $25.17. 826,116 shares of the company's stock traded hands, compared to its average volume of 931,138. Structure Therapeutics Inc. has a 12 month low of $13.22 and a 12 month high of $62.74. The firm has a market capitalization of $1.44 billion, a PE ratio of -34.01 and a beta of -1.69. The firm has a 50 day moving average price of $21.09 and a two-hundred day moving average price of $26.64.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, equities analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

GPCR has been the subject of a number of research reports. Citigroup initiated coverage on Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective for the company. William Blair started coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, HC Wainwright lowered their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Monday. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $78.00.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.